Dr Cathy Eng discusses a study into trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer.
The primary outcome was that the meta-analysis study suggested that FTD/TPI + BEV provides benefits over FTD/TPI in patients with refractory mCRC and has a similar safety profile, but it is associated with a higher rate of grade ≥3 neutropenia.
Dr Eng concludes the by discussing the significance of the study findings
Watch Dr Yoshino's press conference here
Watch Dr Yoshino's interview on the study here
Watch Dr Cremolini comment on the study here
Read the news story on the study here